雌激素和雄激素受体在肺癌中的表达  

Expression of ER and AR in lung cancer

作　　者：闫明[1] 陈小兵[2] 王淑玲[3] 李印[1] 

机构地区：[1]河南省肿瘤医院胸外科,450008 [2]河南省肿瘤医院肿瘤内科,450008 [3]郑州大学基础医学院

出　　处：《中国肺癌杂志》2008年第1期126-129,共4页Chinese Journal of Lung Cancer

基　　金：河南省杰出青年科学基金项目(No．04120001000)资助~~

摘　　要：背景与目的男性与女性肺癌流行病学表现明显不同,可能与性激素水平有关,有数据显示性别因素是肺癌明显独立的预后因子。本研究通过检测雌激素受体(ER)、雄激素受体(AR)在肺癌中的表达,探讨其与临床和病理学特征之间的关系。方法应用免疫组化S-P法检测105例(男84,女21)肺癌组织标本中ER、AR的表达。结果ER和AR总阳性率分别为14.3%(15/105)和20%(21/105)。肺癌组织中ER阳性表达率与患者年龄、性别、肿瘤组织学类型、组织分化程度及TNM分期、肿块大小、淋巴结转移情况等无关。AR的阳性表达与患者年龄、性别、肿瘤组织学类型、组织分化程度及肿块大小等情况无关,而在Ⅲ期肺癌患者中显著高于Ⅰ期肺癌,淋巴结转移N2组与N0组之间也存在统计学差异(x^2=4.7828,P=0.0287)。结论ER阳性表达与肺癌的生物学行为可能无关。AR的阳性表达与肺癌进展和淋巴结转移程度可能相关。Background and objective Epidemiology of lung cancer differs between sexes and it might be partially explained by different sex hormone levels in women and men. There are some epidemiological data indicating that gender is a significant, independent prognostic factor in lung cancer. The aim of this study is to determine expression of ER （estrogen receptor） and AR （androgen receptor） in lung cancer, and evaluate the relationship between their expression and clinical or pathologic characteristics. Methods Immunohistochemistry assay was used to detect expression of ER and AR. Results Positive expression of ER and AR were 14.3%（15/105） and 20%（21/105）. Positive expression of ER had no relationship with age, gender, pathology, histological differentiation, TNM staging, size of tumor and lymph node metastasis. Although age, gender, pathology, histological differentiation and size of tumor had no effect on the expression of AR, positive rate of AR in staging Ⅲ lung cancer was significantly higher than that in staging Ⅰ lung cancer. The different AR expression was significant between NO and N2 lymph node metastasis （X^2= 4.7828,P=-0.0287）. Conclusion The expression of ER has no relationship with biological behavior. Positive expression of AR may be correlated with the progression and the lymph node metastasis of lung cancer.

关 键 词：肺肿瘤 雌激素受体 雄激素受体 

分 类 号：R734.2[医药卫生—肿瘤]